369 Direct anti-psoriatic effect of Apremilast on epidermal keratinocytes

Psoriasis developed through abnormal crosstalk between the immune cells and epidermal keratinocytes. Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor and has been approved for the treatment of patients with plaque psoriasis and psoriatic arthritis. Cyclic adenosine monophosphate (cAMP) has a significant role as a secondary messenger and PDE4 degrades intercellular cAMP to AMP. It is widely recognized that PDE4 inhibition by Apremilast increases intracellular cAMP levels in immune cells, thereby in turn suppress the expression of proinflammatory cytokines, such as TNF- α, IFN-γ and IL-23, which are all linked to psoriasis development.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Innate Immunity and Inflammation Source Type: research